Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

10.64 +1.27 (+13.55%)
Streaming Delayed Price Updated: 1:43 PM EDT, May 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
32 33 Next >
News headline image
6 Largest Psychedelic Compound-Based R & D Stocks In Decline ↗
The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 2.6%, on average, this week and are now only up 6.5% YTD. 
Via Talk Markets
News headline image
Compass Pathways Explores AI-Powered Predictive Model On Psilocybin Therapy For Depression ↗
COMPASS Pathways plc (NASDAQ: CMPS) shared the results from research on the potential of its novel AI technologies to support its proprietary COM 
Via Benzinga
Topics Artificial Intelligence
News headline image
6 Largest Psychedelic Compound-Based R & D Stocks Up 4%, On Average, Last Week ↗
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were UP 3.9%, on average, last week and are now only UP 9.4% YTD. 
Via Talk Markets
News headline image
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More ↗
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety 
Via Benzinga
News headline image
The Latest Analyst Ratings for Compass Pathways ↗
 
Via Benzinga
News headline image
August Recap: Largest Psychedelic Compound-Based R & D Stocks Down 15% ↗
The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 15.0%, on average, in August and are now only up 5.3% YTD. 
Via Talk Markets
News headline image
Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More ↗
Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials 
Via Benzinga
News headline image
3 Cathie Wood Stocks With Parabolic Growth Potential, According to Wall Street ↗
These cutting-edge biotech stocks could deliver life-changing gains for early shareholders. 
Via The Motley Fool
News headline image
6 Largest Psychedelic Compound-Based R&D Stocks Continued Downwards, On Average, This Week ↗
Only 2 of the 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were up this week. 
Via Talk Markets
News headline image
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports ↗
Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds 
Via Benzinga
Topics Cannabis Economy
News headline image
Largest Psychedelic Compound-Based R&D Stocks Continue Downward Trend ↗
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were down an average of 6% last week and are now down 17.2% MTD. We take a look at them in... 
Via Talk Markets
News headline image
COMPASS' Securities Purchase Agreement Is Big News ↗
It’s still cannabis earnings season, but we’re also turning to look at some of the news from the psychedelics industry. ... 
Via Benzinga
Topics Cannabis
News headline image
Up To $285M In Financing: COMPASS Pathways' Private Placement Backed By 'Select Group' Of Investors ↗
Psychedelics biotech giant COMPASS Pathways (NASDAQ: CMPS) has entered into a securities purchase agreement for an initial $125 million and potential additional of $160 million, with a select group of... 
Via Benzinga
News headline image
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More ↗
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published 
Via Benzinga
News headline image
So Far, August Isn't Kind To 4 Of 6 Constituents In Our Psychedelic Drug Stocks Index ↗
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index are down an average of 11.9% so far in August but are still up YTD. 
Via Talk Markets
News headline image
Atai's Q2 2023 Plus Clinical Data On Ibogaine-Opioid Study, Pipeline's Psilocybin, DMT, Ketamine & MDMA ↗
Atai Life Sciences (NASDAQ: ATAI) reported its consolidated, unaudited financial results for the second quarter 2023 ended June 30. Numbers show: 
Via Benzinga
News headline image
Compass Pathways Plc (CMPS) Q2 2023 Earnings Call Transcript ↗
CMPS earnings call for the period ending June 30, 2023. 
Via The Motley Fool
News headline image
COMPASS Pathways Q2 2023: $148.2M Cash Position, Steady Quarter And 'Strong Progress Across The Business' ↗
Psychedelics biotech COMPASS Pathways’ (NASDAQ: CMPS) consolidated unaudited financial results for the second quarter 2023, ended June 30 are as follows: 
Via Benzinga
News headline image
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More ↗
A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances... 
Via Benzinga
News headline image
July Summary: Largest Psychedelic Compound-Based R&D Stocks Up 16%, On Average ↗
All but 1 of the 6 largest psychedelic compound-based research & development stocks advanced in July and are ranked below as to their performances so far in July: 
Via Talk Markets
News headline image
Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial ↗
UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023: 
Via Benzinga
News headline image
This Unexpected Development Is Yet Another Green Flag for Compass Pathways Stock ↗
For biotechs developing psychedelic therapies, good news comes in many forms. 
Via The Motley Fool
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031
EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Compass' Psilocybin Therapy Proves Helpful In Treating Anorexia: Clinical Trial Shows ↗
UC-San Diego authors assessed psilocybin therapy’s potential as a treatment for anorexia nervosa. They recently shared what are believed to be the first results from such a research study, and the... 
Via Benzinga
AMA Issues Details On First Psychedelics Therapy CPT Code – Thanks To These Psychedelic-Focused Mental Healthcare Companies
By Rachael Green, Benzinga 
Via TheNewswire.com
AMA Issues Details On First Psychedelics Therapy CPT Code – Thanks To These Psychedelic-Focused Mental Healthcare Companies
--News Direct-- 
Via News Direct
News headline image
Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa's Magic Pitch & More ↗
Minneapolis Mayor Deprioritizes Psychedelics: 'We Should Be In The Business Of Helping People' Minneapolis Mayor Jacob Frey recently signed an executive order effectively deprioritizing criminal... 
Via Benzinga
News headline image
AMA Issues Details On First Psychedelics Therapy CPT Code – Thanks To These Psychedelic-Focused Mental Healthcare Companies ↗
The American Medical Association’s (AMA) Panel recently released the full details of a new code for psychological support during the administration of psychedelic treatments. 
Via Benzinga
News headline image
Largest Psychedelic Compound-Based Drug Stocks Up 14% MTD; Now Up 27% YTD ↗
The psychedelic compound-based drug research and development sector is UP 13.6% MTD and is now UP 26.6% YTD and this article analyzes the performance of the 6 largest stocks in the Psychedelic Drug... 
Via Talk Markets
News headline image
Jim Cramer Says It's Time To Buy This Financial Services Stock Down 32% YTD ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Illumina, Inc. (NASDAQ: ILMN) is not even as good as Danaher Corporation (NYSE: DHR). 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.